In the treatment of SLE, the accumulation of SLE lymphocytes in S and G2/M cell cycle stages is related to the increased activity of PI3K/Akt/mTOR signaling pathway [37]. This evidence concerns the gene AKT1 and systemic lupus erythematosus.